Warhound Secures $200M to Genetically Engineer Elite Canine Workforce

The U.S. defense sector has long relied on foreign sources for a critical component of its operational capacity: working dogs. On Thursday, Warhound emerged from stealth mode with a $200 million funding round that values the company at $1.2 billion, signaling a major shift toward domestic, technologically enhanced canine solutions.

The new venture is backed by a mix of prominent tech and intelligence-linked investors, including Sequoia, 8VC, Corner Ventures, and In-Q-Tel, a firm supported by U.S. intelligence agencies. The capital injection is designed to accelerate the development of dogs engineered for specific high-risk tasks, such as bomb detection and hazardous searches, where human exposure is costly and machine limitations are significant.

The business case rests on a visible supply chain gap. Warhound’s launch materials note that more than 80% of the U.S. military’s current working dogs are imported from Europe, with fewer than half meeting fitness standards upon arrival. This reliance creates a vulnerability in a key operational asset. By engineering dogs with specific physical and sensory traits, the company aims to create a self-sufficient, high-performance supply chain for defense and law enforcement.

The venture is a joint effort between Colossal Biosciences and Anduril. Colossal, known for its de-extinction projects, will provide the genetic engineering technology to enhance the dogs' health, longevity, and specific abilities like olfactory sensitivity. Anduril will supply the hardware and software ecosystem, including protective vests and goggles equipped with data sensors. This integration allows handlers to receive real-time situational awareness from the dogs, effectively turning the animals into mobile sensor platforms.

Palmer Luckey, the founder of Anduril, is a partner in the venture but holds no equity, while Colossal retains ownership and licenses its technology. Ben Lamm of Colossal stated that the first batch of clones is currently in incubation, with births expected early next year. The company targets full service entry within two years, leveraging Viagen’s cloning technology, which Colossal notes has a high success rate in its endangered species programs.

The company has not yet disclosed its pricing model but expects to sell to the Department of Defense, police forces, and other emergency responders. To address ethical concerns regarding genetically modified animals, Warhound is working under the guidance of the American Humane Society to certify its training programs. The society stated it looks forward to ensuring the animals are treated humanely, with a goal of integrating retired Warhound dogs into its reunification programs for new homes.

With the initial cloning phase underway, the market will soon see the first tangible results of this biological venture. The two-year timeline to full service suggests a rapid deployment strategy, potentially reshaping how the U.S. military procures and utilizes its four-legged assets in the coming fiscal years.